Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet DAXANLO 150mg capsules
- Product code:
- W69917003
- Quantity:
- 60
- Indicated for:
- prevention and treatment of thromboembolism
- Route of administration:
- oral
- Substance:
- dabigatran etexilat (anticoagulant)
- ATC
- B01AE07 — Blood and blood forming organs | Antithrombotic agents | Antithrombotic agents | Direct thrombin inhibitors
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Dabigatran etexilate is an oral anticoagulant used for the prevention and treatment of blood clots. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.
Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.
Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.
Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.
General data about DAXANLO 150mg
- Substance:
- dabigatran etexilat
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W69917003
- Concentration:
- 150mg
- Pharmaceutical form:
- capsules
- Quantity:
- 60
- Product type:
- Generic medicine
- Price:
- 150.43 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for dabigatran etexilat
Concentrations available for dabigatran etexilat
- 110mg
- 150mg
- 20mg
- 30mg
- 40mg
- 50mg
- 6.25mg/ml
- 75mg
Compensation lists for DAXANLO 150mg KRKA
B - Sublist B with 50% discount from the reference price
- Price
- 150.43 RON
- Copayment
- 75.21 RON
- Patient
- 75.22 RON